Boston Scientific (BSX) EBITDA (2009 - 2026)

Boston Scientific (BSX) has 18 years of EBITDA data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 19.54% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $3.8 billion (up 33.13% YoY), and the FY2025 full-year result was $3.6 billion, up 38.8% from the prior year.
• EBITDA grew to $1.1 billion in Q1 2026, from $825.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.1 billion in Q1 2026 to a low of $358.0 million in Q3 2022.
• A 5-year average of $665.2 million and a median of $675.0 million in 2024 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 123.33% in 2022, while the deepest fall reached 7.49% in 2022.
• Tracing BSX's EBITDA over 5 years: stood at $402.0 million in 2022, then jumped by 45.27% to $584.0 million in 2023, then increased by 15.58% to $675.0 million in 2024, then rose by 22.22% to $825.0 million in 2025, then jumped by 33.45% to $1.1 billion in 2026.
• Business Quant data shows BSX's EBITDA at $1.1 billion in Q1 2026, $825.0 million in Q4 2025, and $1.0 billion in Q3 2025.